Ricky D. Turgeon

Introduction The PHARM‐HF clinic is a novel, pharmacist‐led medication optimization clinic for patients with heart failure with reduced ejection fraction (HFrEF). PHARM‐HF aims to achieve maximum‐tolerated HFrEF guideline‐directed medical therapy (GDMT) as outlined by the latest Canadian Cardiovascular Society heart failure guidelines. Methods This retrospective pre‐post study evaluated consecutive patients attending PHARM‐HF (January 2021–August 2022). The primary outcome was the modified Optimal Medication Therapy (mOMT) score, an aggregate score of HFrEF quadruple therapy. The mOMT score was categorized as suboptimal (score 0–4), acceptable (score 5–7), or optimal (score 8; all four drugs at maximum tolerated dose). Secondary outcomes included change in left ventricular ejection fraction (LVEF) from baseline to 1 year, and Kansas City Cardiomyopathy Questionnaire‐12 (KCCQ; range 0 [worst] to 100 [best]) from baseline to discharge. Results Of 81 included patients, median age was 68 years, 21% were female, 61% had New York Heart Association (NYHA) class 2 functional capacity, and median LVEF was 30%. Median mOMT improved from 6 (interquartile range [IQR] 4–7) at baseline to 8 (IQR 7–8) at clinic discharge ( p < 0.001; increase from 7% to 73% categorized as optimal). LVEF improved from a median of 30% to 38% at 1 year ( p < 0.001). Among 16 patients who completed the KCCQ‐12 at both time points, the score was 62 at baseline and 77 at discharge ( p = 0.42). Conclusions Uptake of GDMT significantly increased from admission to discharge from the PHARM‐HF medication optimization clinic, during which other cardiovascular clinicians did not modify HFrEF medications. Furthermore, there was an improvement in LVEF at 1 year. A pilot randomized controlled trial is currently underway to guide the development of a multicenter trial to provide definitive evidence for the role of pharmacist‐led medication optimization in HFrEF.